Loading...
Interleukin-1 receptor antagonist treatment in acute ischaemic stroke does not alter systemic markers of anti-microbial defence
Background: Blockade of the cytokine interleukin-1 (IL-1) with IL-1 receptor antagonist (IL-1Ra) is a candidate treatment for stroke entering phase II/III trials, which acts by inhibiting harmful inflammatory responses. Infection is a common complication after stroke that significantly worsens outc...
Na minha lista:
| Udgivet i: | F1000Res |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
F1000 Research Limited
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6820822/ https://ncbi.nlm.nih.gov/pubmed/31700615 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12688/f1000research.19308.2 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|